文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 电子/电路 > Serratiopeptidase A systematic review of the existing evidence
侵权投诉

Serratiopeptidase A systematic review of the existing evidence

210

S.Bhagatetal./InternationalJournalofSurgery11(2013)209e217

hasbeenusedforreducingin ammation.1e7Entericcoatedoralformulationofthisenzymeisbeingusedcommonlyinvariousspecialitieslikesurgery,orthopaedics,otolaryngology,gynaecologyanddentistryforitsanti-in ammatoryandanti-edemicproperties.Theuseofenzymesliketrypsin,8chymotrypsin,9bromelain10asanti-in ammatoryagentscameintopracticeafteritwasobservedduring1950sinUSAthatparenteraltrypsincouldbeusedtorelievepost-surgicalin ammationandthatduetotraumaticinjurycausedbysports8aswellasin ammationduetoconditionslikerheu-matoidarthritis,ulcerativecolitis,andatypicalviralpneumonia.

ThisobservationwassoonfollowedbytheuseofSerratio-peptidase2foritsanti-in ammatoryeffectsinJapanforthe rsttime.Laterduring1960stheseparenteralenzymeformulationswerereplacedbytheirentericcoatedsuccessorstobeusedorally.During1980sand1990sitwasproposedbyseparateresearchconductedinEuropeandJapanthatSerratiopeptidasewasthemosteffectiveagentinreducingin ammationamongallotherenzymepreparations.1,3Serratiopeptidasehence,hasbeenusedforalmost40yearsinJapanandEuropeforpainandin ammationduetoarthritis,trauma,surgery,sinusitis,bronchitis,carpaltunnelsyn-dromeandpainfulswellingofbreasts.Apartfromitsanti-in ammatoryactivity,Serratiopeptidaseisalsosaidtopossessanalgesicandanti-atheroscleroticeffects.Thissystematicreviewisanattempttocriticallyexaminetheavailableevidencewhichexistsasregardstheef cacyandsafetyofSerratiopeptidase.2.Evidenceacquisition2.1.Searchcriteria

Toidentifyarticles,wesystematicallysearchedelectronicda-tabasesandcommercialwebsitesforpublishedandunpublishedstudies,appliedinclusioncriteriaandperformedqualityappraisals.ThedatabasessearchedincludetheCochraneLibrary,PubMed,MEDLINE,theControlledtrialsregistryClinicalTrials.gov,Google,Dogpile.AmanualsearchfromreferencelistsofrelevantarticleswasconductedandPharmaceuticalcompanieswerecontactedthroughemailsforadditionalinformationonpharmacokinetics,pharmacodynamics,ef cacyandsafetyofSerratiopeptidase.The

followingsearchtermswereusedeitherindependentlyofeachotherorincombinations:Serratiopeptidase,serrapeptase,serra-tiopeptidase,proteolyticenzymes,pharmacokinetics,pharmaco-dynamics,anti-in ammatoryagents,danzen,serratiapeptase,serralysin,adversedrugreactions.2.2.Inclusioncriteria

EligiblestudieswererequiredtoreportresultsonSerratio-peptidaseef cacyandsafety.Allarticlesavailableonef cacywereincluded.Allarticleswererequiredtobecompleteandavailableinenglish.Studieswereselectedforinclusioninoursystematicre-viewiftheymettheinclusioncriteria:double-blind,single-blind,openlabel,placebo-controlled,randomisedcontrolledtrials,meta-analysisofRCTs,prospectivetrialsorpreclinicalstudies.

Atotalof24studiesonclinicalef cacyofSerratiopeptidasemettheinclusioncriteria.Amongwhich18wereclinicaltrials(including14RCTs,3prospectivetrialsandin1trialstudydesignnotstated)and6werepreclinicalanimalstudies.AsSerratio-peptidasehasbeeninclinicaluseforin ammationandpainforanumberofyearsandisbeingpromotedthesedaysforitsanti-atheroscleroticeffectsalso.Butdataonitsanalgesicandanti-atheroscleroticef cacywasfoundtobelacking.TheRCTswereonlyafewinnumbers(14RCTsintotalexcludingtheduplicatedstudies,11RCTsfoundonCochraneLibraryand9onPubMedsearch).Theyhadalimitedpopulation,notmorethan150patientspergroupinanyofthestudiesandwereofshortduration.Thereforeprospectivestudiesaswellaspreclinicalstudieswerealsoincludedtoappraiseevidenceonef cacyofSerratiopeptidase.2.3.Qualityappraisal

CriticalappraisalofstudieswasconductedusingPRISMA11statement(Fig.1)whiletheScottishIntercollegiateGuidelinesNetwork(SIGN)12gradingforRCTswasusedfororiginalstudiesbytwoseparatereviewersandthencoordinatedtogethertovalidatethe nalgrading.Thiswasdonetofacilitatetransparentandcomprehensivereportingofresults.Anydisagreementbetweenthetworeviewerswasresolvedbydiscussionwiththethird

Serratiopeptidase A systematic review of the existing evidence

reviewer.

Fig.1.Preferredreportingitemsforsystematicreviewsandmeta-analysis(PRISMA)11 owdiagramofstudiesincludedinthereviewofef cacyofserratiopeptidase.

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email